Study outcome won't sway company on eye drug
User rating: 5 / 5 after 10 vote(s)
(AP) -- What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000? In the case of Genentech Inc., nothing.
Full story »
|

PhysOrg Forum
Video
Editorials
Free Magazines
Newsletter
Goto Archive
Suggest a story idea
Send feedback